ManagedCareCGM

This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit CanadaCGM.com

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Featured Resources

Search
Generic filters

Lower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring

Released: September, 2021

 

 

Click here to view the infographic

 


Optimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring

Released: June, 2021

 

Click here to view the infographic


Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoring

Source: Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoringa symposium at the Academy of Managed Care Pharmacy 2021 Virtual Annual Meeting.

Featuring expert faculty:

Jeffrey Dunn, PharmD, MBA
Head of Clinical Pharmacy
Berkshire Hathaway/Geico
(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management

Maria Lopes, MD, MS
Former Chief Medical Officer
Magellan Health
Former Practicing Obstetrician and Gynecologist

Janet B. McGill, MD, MA, FACE, FACP
Professor of Medicine
Washington University School of Medicine

Vanita Pindolia, PharmD, BCPS, MBA
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan

Key Takeaways: 

  • All insulin treated members,  particularly high-risk older adults, should have streamlined access to real-time CGM, and payers should reconsider coverage criteria, such as removing intensive insulin eligibility criteria for T2D and streamlining the documentation requirements.
  • Pharmacy coverage and access for appropriate subpopulations can confer immediate cost savings.
  • Consensus guidelines recommend the use of rtCGM in pregnant women with pre-existing T1 and T2D and GDM. A delay in access to CGM can have adverse consequences in terms of both maternal and neonatal outcomes.
  • rtCGM allows for a new frontier of diabetes management through remote monitoring and innovative patient engagement in telemedicine initiatives.

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.